

# Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022

Sandra Garba-Ouangole,<sup>1</sup> Josephine Bourner,<sup>1</sup> Festus Mbrenge, Ella Gonofio, Benjamin Selekon, Alexandre Manirakiza, Ernest Kalthan, Christian Malaka, Yap Boum II, Piero Olliaro,<sup>2</sup> Emmanuel Nakouné<sup>2</sup>

During 2016–2022, PCR testing confirmed 100 mpox cases among 302 suspected cases in the Central African Republic. The highest detection rates were from active lesions (40%) and scabs (36%); cycle thresholds were lower ( $\approx 18$ ) than those for blood samples ( $\approx 33$ ). Results were consistent for generic primer- and clade I primer-specific PCR tests.

Mpox is caused by the monkeypox virus (MPXV), a double-stranded DNA orthopoxvirus with 2 known clades: clade I (formerly Congo Basin or Central African clade); and clade II (formerly West African clade), which encompasses 2 subclades (IIa and IIb) (1–3). Cases of mpox have been identified in the Central African Republic (CAR) since 2001 and have increased over time (4). The growing number of cases can be explained by the widening geographic spread of the disease and intensified case-finding activities (5). However, official figures probably underestimate the incidence of mpox, which principally occurs in remote areas, where many cases may go undetected because of a lack of diagnostic capacity.

The Ministry of Health and Population set up a passive surveillance program for mpox in 2010. Under this program, specimens are collected from all suspected case-patients with illness meeting the standardized case definition (Appendix, <https://wwwnc.cdc.gov/EID/article/29/9/23-0514-App1.pdf>), which is disseminated to all health professionals in CAR through regular training sessions and posters

displayed in health facilities. Specimens are sent for biologic confirmation by PCR to the national reference laboratory at Institut Pasteur de Bangui (IPB). Whenever possible, contact tracing is conducted after identification of confirmed cases.

Since 2016, each specimen received at IPB is tested for MPXV by real-time PCR. After specimen processing, 200  $\mu\text{L}$  of each sample are extracted by using the QIAamp Viral DNA Mini Kit (QIAGEN, <https://www.qiagen.com>) according to the manufacturer's instructions. The reactions are performed in 25  $\mu\text{L}$  volume containing 12.5  $\mu\text{L}$  of TaqMan Universal PCR Master Mix (Thermo Fisher Scientific, <https://www.thermofisher.com>), 4.5  $\mu\text{L}$  of nuclease-free water (Thermo Fisher), 1  $\mu\text{L}$  of each 10  $\mu\text{mol/L}$  primer developed by TaqMan technology (Thermo Fisher), using the generic primer (G2RG) and clade I-specific (C3L) primers and 5  $\mu\text{L}$  of extracted DNA (6). On the basis of these same concentrations, varicella zoster virus (VZV) primers (VZV open reading frame 63) are also used (7).

## The Study

We conducted a retrospective descriptive study. By using results from all specimens collected from patients with suspected mpox under the national mpox surveillance program during 2016–2022, we aimed to describe the mpox landscape in CAR and evaluate the agreement of mpox test results (including cycle threshold [Ct] values) generated using the G2RG and C3L primers and different specimen types (blood, active lesion, or scab).

During 2016–2022, a total of 494 specimens (278 blood, 99 active lesion, 95 scab, and 22 oropharyngeal) from 302 patients were received and tested for suspected mpox at IPB. Of the total 302 suspected

Author affiliations: Institut Pasteur de Bangui, Bangui, Central African Republic (S. Garba-Ouangole, F. Mbrenge, E. Gonofio, C. Malaka, Y. Boum II, E. Nakouné); International Severe Acute Respiratory and Emerging Infection Consortium, Pandemic Sciences Institute, University of Oxford, Oxford, UK (J. Bourner); Ministry of Health and Population, Bangui (B. Selekon, A. Manirakiza, E. Kalthan)

DOI: <https://doi.org/10.3201/eid2909.230514>

<sup>1</sup>These first authors contributed equally to this article.

<sup>2</sup>These senior authors contributed equally to this article.


case-patients, 105 (35%) were positive for MPXV on >1 specimen (varying 19%–64% annually) (Figure 1). Of the 105 MPXV-positive patients, 3 (3%) were also positive for VZV. Of the 197 MPXV-negative patients, 82 (42%) were positive for VZV and 108 (55%) were negative for both MPXV and VZV. The remaining 7 patients were not tested for VZV.

The highest percentage of MPXV-positive specimens derived from the Lobaye and Mbomou prefectures, which together contributed 58% of mpx cases overall. MPXV detection rates varied by prefecture: Sangha Mbaere, 24/40 specimens (60%); Lobaye, 35/106 specimens (33%); Mbomou, 25/74 specimens (34%); and Bangui 2/41 specimens (5%) (Appendix Table 1).

Significantly more female patients were among MPXV-positive than VZV-positive case-patients ( $p = 0.03$ ) but not among case-patients who were negative for both viruses. The median age across all suspected case-patients was 14 years; we observed no statistically significant difference between the median ages of confirmed case-patients with mpx (17 years) and VZV (20 years) infections. The median age of case-patients who tested negative on both tests was significantly lower (9 years) (Appendix Table 1).

Blood specimens were positive for MPXV on G2RG in 77/278 (28%) of cases, active lesions in 45/102 (44%), scabs in 36/98 (37%), and oropharyngeal specimens in 3/22 (14%) (Table 1). Of specimens returning a positive result on G2RG, the median Ct was 32.11 (interquartile range [IQR] 29.12–35.45) for blood specimens, 18.92 (IQR 17.42–23.43) for active lesions, 18.07 (16.19–19.82) for scabs, and 30.15 (28.04–32.56) for oropharyngeal specimens (Table 2). Similar values were returned by C3L. For paired specimens (Appendix Table 2), we observed either substantial ( $\kappa$  0.61–0.80) or almost perfect ( $\kappa$  0.81–1.00) agreement of a positive or negative result on pairwise comparisons of tests conducted on different specimen types on either G2RG or C3L.

The Ct values of G2RG and C3L on blood were significantly higher than in active lesion and scabs, whereas we observed no difference between active lesion and scab specimens. We observed no statistically significant difference between the Ct values



**Figure 1.** Laboratory test results for persons with suspected mpx cases, by year, Central African Republic, 2016–2022. Of 302 suspected cases during the study period, 105 (35%) had positive results for monkeypox virus on >1 specimen.

generated on G2RG and C3L on the same specimens. (Figure 2)

## Conclusions

Approximately one third of suspected mpx cases in CAR are confirmed MPXV infections; an additional 2/5 are VZV infections, leaving  $\approx 3/5$  cases of papulovesicular cutaneous eruptions undiagnosed. Most mpx and VZV infections were diagnosed in teenagers and young adults, with an even younger population remaining undiagnosed.

Although cases of mpx are generally detected across the heavily forested, southern parts of CAR, mpx detection rates vary across prefectures. Some prefectures, such as Sangha Mbaere, have a high detection rate of MPXV (60%) over VZV (5%), whereas in others, such as Bangui, detection is much lower (MPXV 5%, VZV 46%). The varying detection rates between prefectures could be linked to local lifestyles and practices, as well as social instability. In the southwest region, local communities primarily subsist through hunting and gathering, spending long periods in mpx-endemic forest, which may increase the risk for exposure to the virus; however, in the southeast, mpx-endemic bushlands are used for farming and as a place of passage or temporary habitation for communities that have been displaced by social instability.

Our study also detected significantly more female patients among mpx-positive than VZV-positive

**Table 1.** Test results by specimen type and test type for MPXV and VZV in a study assessing laboratory diagnosis of mpx, Central African Republic, 2016–2022\*

Specimen type	MPXV (G2RG)		MPXV (C3L)		VZV	
	Positive	Negative	Positive	Negative	Positive	Negative
Blood	77/278 (28)	201/278 (72)	73/278 (26)	205/278 (74)	62/260 (24)	198/260 (76)
Active lesion	45/102 (44)	57/102 (56)	45/102 (44)	57/102 (56)	42/108 (39)	66/108 (61)
Scab	36/98 (37)	62/98 (63)	37/98 (38)	61/98 (62)	38/100 (38)	62/100 (62)
Oropharyngeal	3/22 (14)	19/22 (86)	2/22 (9)	20/22 (91)	6/22 (27)	16/22 (73)

\*Data are no. positive/no. tested (%). C3L, clade I-specific primer; G2RG, generic primer; MPXV, monkeypox virus; VZV, varicella-zoster virus.

**Table 2.** Cycle threshold values obtained using G2RG and C3L PCR primers on different specimens in a study assessing laboratory diagnosis of mpox, Central African Republic, 2016–2022\*

Specimen type	MPXV (G2RG)	MPXV (C3L)	VZV
Blood	32.11 (29.12–35.45)	32.93 (30.25–35.94)	34.41 (31.38–36.01)
Active lesion	18.92 (17.42–23.43)	19.61 (18.05–23.57)	19.23 (17.69–20.82)
Scab	18.07 (16.19–19.82)	18.13 (16.46–21.46)	15.78 (13.63–18.42)
Oropharyngeal	30.15 (28.04–32.56)	28.19 (26.79–29.59)	34.31 (32.95–35.67)

\*Data are median cycle threshold value (interquartile range). C3L, clade I-specific primer; G2RG, generic primer; MPXV, monkeypox virus; VZV, varicella-zoster virus.

cases, which may be explained by increased risk for infection through multiple routes of exposure to potentially infected sources. For example, women are primarily responsible for skinning and cooking wild game hunted in the forest and are the primary caretakers for family members who fall ill.

Our results demonstrate very high agreement in PCR results between primers. The results also highlight the need to prioritize active lesion and scab specimens over blood specimens, given that their relatively higher viral loads for MPXV and VZV enable better detection.


CAR faces special geographic, social, and healthcare challenges, leading to substantial delays between symptoms onset, diagnosis, and care. The reported case-fatality ratio for clade I mpox cases varies widely and is often cited as 11% (8) but has also been as low as 1.4% in Democratic Republic of Congo (P.R. Pittman et al., unpub. data, <https://doi.org/10.1101/2022.05.26.22273379>) and 6.7% in CAR (9). To improve patient outcomes in CAR, diagnostic capacity needs to be strengthened through greater

availability of point-of-care testing and through support by more active epidemiologic and genomic surveillance that can be implemented with a wider range of partners.

This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome (grant no. 215091/Z/18/Z), the Bill and Melinda Gates Foundation (grant no. OPP1209135), and the African Coalition for Epidemic Research, Response and Training (ALERRT). ALERRT is part of the European and Developing Countries Clinical Trials Partnership 2 program supported by the European Union (grant no. RIA2016E-1612). ALERRT is also supported by the United Kingdom's National Institute for Health Research.

### About the Author

Ms. Garba-Ouangole is an assistant technical supervisor at Institut Pasteur de Bangui in the Central African Republic. Her primary research interests include genomic surveillance and surveillance of emerging and reemerging infectious diseases and zoonoses.



**Figure 2.** Distribution of Ct values obtained using G2RG and C3L primers of monkeypox virus-positive active lesion, blood, and scab specimens in study assessing laboratory diagnosis of mpox, Central African Republic, 2016–2022. C3L, clade I-specific primer; Ct, cycle threshold; G2RG, generic primer.

### References

- Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, et al. Monkeypox. *Lancet*. 2023;401:60–74. [https://doi.org/10.1016/S0140-6736\(22\)02075-X](https://doi.org/10.1016/S0140-6736(22)02075-X)
- Gessain A, Nakoune E, Yazdanpanah Y. Monkeypox. *N Engl J Med*. 2022;387:1783–93. <https://doi.org/10.1056/NEJMra2208860>
- Mansour R, Houston A, Majeed A, Boum Y II, Nakouné E, Razai MS. Human monkeypox: diagnosis and management. *BMJ*. 2023;380:e073352. <https://doi.org/10.1136/bmj-2022-073352>
- Berthet N, Descorps-Declère S, Besombes C, Curaudeau M, Nkili Meyong AA, Selekon B, et al. Genomic history of human monkey pox infections in the Central African Republic between 2001 and 2018. *Sci Rep*. 2021;11:13085. <https://doi.org/10.1038/s41598-021-92315-8>
- Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, et al. Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. *Infect Dis Clin North Am*. 2019;33:1027–43. <https://doi.org/10.1016/j.idc.2019.03.001>
- Li Y, Zhao H, Wilkins K, Hughes C, Damon IK. Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. *J Virol Methods*. 2010;169:223–7. <https://doi.org/10.1016/j.jviromet.2010.07.012>


7. Cohrs RJ, Randall J, Smith J, Gilden DH, Dabrowski C, van Der Keyl H, et al. Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. *J Virol*. 2000;74:11464–71. <https://doi.org/10.1128/JVI.74.24.11464-11471.2000>
8. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox – a potential threat? A systematic review. *PLoS Negl Trop Dis*. 2022;16:e0010141. <https://doi.org/10.1371/journal.pntd.0010141>
9. Besombes C, Mbrennga F, Schaeffer L, Malaka C, Gonofio E, Landier J, et al. National monkeypox surveillance, Central African Republic, 2001–2021. *Emerg Infect Dis*. 2022;28:2435–45. <https://doi.org/10.3201/eid2812.220897>

Address for correspondence: Josephine Bourner, ISARIC Global Support Centre, International Severe Acute Respiratory and Emerging Infection Consortium, New Richards Building, University of Oxford Old Road Campus, Old Road, Oxford OX3 7LG, UK; email: [josephine.bourner@ndm.ox.ac.uk](mailto:josephine.bourner@ndm.ox.ac.uk)

June 2023

## Poxvirus Infections

- Association of Persistent Symptoms after Lyme Neuroborreliosis and Increased Levels of Interferon- $\alpha$  in Blood
- Probable Transmission of SARS-CoV-2 from African Lion to Zoo Employees, Indiana, USA, 2021
- Epidemiologic Characteristics of Mpx among People Experiencing Homelessness, Los Angeles County, California, USA, 2022
- Case Studies and Literature Review of *Francisella tularensis*–Related Prosthetic Joint Infection
- Neurologic Complications of Babesiosis, United States, 2011–2021
- SARS-CoV-2 Seroprevalence Studies in Pets, Spain
- Similar Prevalence of *Plasmodium falciparum* and Non-*P. falciparum* Malaria Infections among Schoolchildren, Tanzania
- Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain
- SARS-CoV-2 Vaccine Effectiveness against Omicron Variant in Infection-Naive Population, Australia, 2022
- Increased Incidence of Legionellosis after Improved Diagnostic Methods, New Zealand, 2000–2020



- Risk for Infection in Humans after Exposure to Birds Infected with Highly Pathogenic Avian Influenza A(H5N1) Virus, United States, 2022
- Results of PCR Analysis of Mpx Clinical Samples, Sweden, 2022
- SARS-CoV-2 Seroprevalence and Cross-Variant Antibody Neutralization in Cats, United Kingdom
- Ranid Herpesvirus 3 Infection in Common Frog *Rana temporaria* Tadpoles
- *Baylisascaris procyonis* Roundworm Infection in Child with Autism Spectrum Disorder, Washington, USA, 2022
- MERS-CoV–Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination
- High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022
- Novel Avian Influenza Virus (H5N1) Clade 2.3.4.4b Reassortants in Migratory Birds, China
- Detection of Leishmania RNA Virus 1 in *Leishmania (Viannia) panamensis* Isolates, Panama
- Enterovirus D68 Outbreak in Children, Finland, August–September 2022
- Risk Factors for Non-O157 Shiga Toxin–Producing *Escherichia coli* Infections, United States
- Evolution of Avian Influenza Virus (H3) with Spillover into Humans, China
- Detection of Novel Poxvirus from Gray Seal (*Halichoerus grypus*), Germany
- Tanapox, South Africa, 2022
- Replication of Novel Zoonotic-Like Influenza A(H3N8) Virus in Ex Vivo Human Bronchus and Lung
- Novel Orthonairovirus Isolated from Ticks near China–North Korea Border

**EMERGING  
INFECTIOUS DISEASES®**

To revisit the June 2023 issue, go to:  
<https://wwwnc.cdc.gov/eid/articles/issue/29/6/table-of-contents>

# Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022

## Appendix

### Case Definitions for Suspected and Confirmed Mpox

The following mpox case definitions are communicated to health professionals across the Central African Republic in training sessions. Flyers containing the case definitions are provided to participants during the training for display at their health facilities in locations visible to anyone who enters.

#### Suspected case

Any patient who presents to a health facility with the following signs and symptoms:

- Fever or suspected fever
- Cutaneous rash over the body, particularly on the palms of the hands or soles of the feet
- Adenopathy

#### Confirmed case

Any patient whose sample is confirmed by PCR for mpox in the laboratory

### Procedure for Mpox Sample Collection

The standard procedures for collection mpox samples are as follows:

- Written or oral consent is obtained from the patient (or a legal guardian if the patient is a minor)
- Completion of the case notification form provided under the national surveillance program

- Trained healthcare personnel collect the following sample(s):
  - Blood is collected at the onset of the acute phase of the disease or during the late phase after all lesions have desquamated
  - If lesions have not scabbed, a lesion swab is collected
  - If lesion have scabbed, the crusts are removed when the lesions have dried but are still stuck to the body
- All samples are sent to the national reference laboratory at Institut Pasteur de Bangui for testing by PCR using G2R-G and C3L primers

**Appendix Table 1.** Summary of age and sex of patients whose samples were sent to IPB for MPXV testing<sup>§</sup>

Characteristic	All	MPXV+ only	VZV+ only	VZV- and MPXV-
Sex, ratio F:M	147:152	52:44*	31:49	56:52
Age (years), median (Q1, Q3) [range]	14 (5,27) [0 to 85]	17 (6,28) [0 to 67]	20 (8, 29) [0 to 80]	9 (2, 21) [0 to 85]
Age (years), mean (std)	18 (14.5)	19 (13.6)	21 (15)	13** (13.9)
Prefecture in which sample collected, N (%)				
Haut Mbomou	1 (<1%)	0 (0%)	0 (0%)	1 (1%)
Nana Mambere	2 (<1%)	0 (0%)	1 (1%)	1 (1%)
Haute Kotto	7 (2%)	3 (3%)	2 (2%)	2 (2%)
Membere Kadei	6 (2%)	3 (3%)	1 (1%)	2 (2%)
Ombella M'poko	6 (2%)	5 (5%)	1 (1%)	0 (0%)
Ouaka	16 (5%)	7 (7%)	2 (2%)	7 (6%)
Sangha Mbaere	40 (13%)	24 (23%)	2 (1%)	15 (14%)
Bangui	41 (14%)	2 (2%)	20 (24%)	19 (19%)
Mbomou	74 (25%)	25 (24%)	23 (28%)	23 (22%)
Lobaye	106 (35%)	35 (33%)	33 (38%)	37 (34%)

<sup>§</sup>3 cases positive for both MPXV and VZV excluded

\*MPXV + vs VZV + chi-square p = 0.03

\*\*MPXV + vs VZV & MPXV- Welch Two Sample t-test = 0.003748; VZV+ vs VZV & MPXV- = 0.0004724

NOTE: MPXV detection rates: Sangha Mbaere = 60%; Lobaye = 33%, Mbomou = 34%; Bangui = 5%

**Appendix Table 2.** Comparison of results between blood and scab samples using the G2RG primer

Comparison	Samples included in pairwise comparisons
Blood v. scab (G2RG)*	82
Blood v. active lesion (G2RG)*	82
Scab v. active lesion (G2RG)*	43
G2RG v. C3L (blood)**	265
G2RG v. C3L (scab)**	93
G2RG v. C3L (active lesion)**	95

\*Comparisons were conducted where the G2RG test was performed on both samples types

\*\*Comparisons were performed where the sample was tested using both primers